New drug MSD-001 tested in healthy volunteers for safety

NCT ID NCT06702332

Completed Knowledge-focused Sponsor: Mindstate Design Labs Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tested a single dose of MSD-001 in 47 healthy adults to see if it is safe and how the body processes it. The drug is being developed as part of a future combination treatment for mental health conditions. The study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MSD-001
What this could lead to: If successful, this study could pave the way for developing a new treatment for mental health disorders.
What could go wrong: This is a very early Phase 1 trial in healthy people, not patients. It only tests safety and dosing, not whether the drug works for any condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENTAL HEALTH DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mental disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENTAL HEALTH DISORDERS

Contacts and locations

Locations

Centre for Human Drug Research

Leiden, South Holland, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.